Ranbaxy gets TGA approval for SEBIFIN Terbinafine tablets

Ranbaxy Laboratories has received an approval from the Australian Government’s Therapeutic Goods Administration (TGA) for the registration of SEBIFIN Terbinafine tablets in Australia.

The marketing authorisation application was submitted by Ranbaxy Australia, a wholly-owned subsidiary of Ranbaxy and with the approval of SEBIFIN, Ranbaxy now has a total number of 26 molecules approved for marketing in Australia since the incorporation of Ranbaxy Australia in 2004.

These cover a wide range of therapeutic areas including anti-hypertensives, anti-infectives, hypolipidaemic agents, anti-convulsants, anti-depressants etc.